Pancreatic Cancer Research

ResearcherGuiyang Medical UniversityNo recent work listed

Qianfan Liu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-9457-1610; OpenAlex author ID A5082854626. Sources: OpenAlex.

Their work

Papers
3
Trials
0
Grants
0
Labs led
0
Collaborators
6
Papers, trials and grants by year

2018: 1 paper · 2019: none · 2020: none · 2021: none · 2022: 1 paper · 2023: 1 paper

Papers 3

  1. LHPP suppresses proliferation, migration, and invasion in hepatocellular carcinoma and pancreatic cancer by inhibiting EGFR signaling pathway. Co-author DOI 10.1007/s12032-023-02127-1↗
  2. E2F2 enhances the chemoresistance of pancreatic cancer to gemcitabine by regulating the cell cycle and upregulating the expression of RRM2. Co-author DOI 10.1007/s12032-022-01715-x↗
  3. Combination of gemcitabine and erlotinib inhibits recurrent pancreatic cancer growth in mice via the JAK-STAT pathway. Co-author DOI 10.3892/or.2018.6198↗

Closest collaborators

The 6 strongest of 6 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Haitao Zhu · 3 shared papers, 2018–2023 · strength 0.46
  2. Liyue Fu · 1 shared paper, 2023 · strength 0.22
  3. Zhirui Zeng · 1 shared paper, 2022 · strength 0.16
  4. Zili Chen · 1 shared paper, 2018 · strength 0.08
  5. Chengyi Sun · 1 shared paper, 2018 · strength 0.08
  6. Liwen Chen · 1 shared paper, 2018 · strength 0.08

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.